Relugolix
FDA-approved product (tablet, oral), marketed as Orgovyx.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Metastatic prostate cancer
- Neoplasm
- Prostate adenocarcinoma
- Prostate cancer
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other hormone antagonists and related agents
- FDA pharmacologic class
- Gonadotropin Releasing Hormone Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Relugolix with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
NCT02135445 · start 2014-06
Registered record
- Registry ID
- NCT02135445
- Conditions
- Prostate Cancer
- Interventions
- TAK-385; Degarelix
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-06
- Completion
- 2015-12
- Enrolment
- 103
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionTAK-385; DegarelixPhasePhase 2Registry statusCompletedA Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer
NCT02141659 · start 2014-05-01
Registered record
- Registry ID
- NCT02141659
- Conditions
- Hormone Treatment-naïve Participants With Prostate Cancer
- Interventions
- TAK-385
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-05-01
- Completion
- 2017-04-20
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHormone Treatment-naïve Participants With Prostate CancerInterventionTAK-385PhasePhase 1Registry statusCompletedA Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
NCT02083185 · start 2014-03-26
Registered record
- Registry ID
- NCT02083185
- Conditions
- Prostate Cancer
- Interventions
- Relugolix; Leuprorelin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-03-26
- Completion
- 2017-02-23
- Enrolment
- 136
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionRelugolix; LeuprorelinPhasePhase 2Registry statusCompletedA Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
NCT02093390 · start 2014-03
Registered record
- Registry ID
- NCT02093390
- Conditions
- Prostate Cancer; Endometriosis
- Interventions
- TAK-385; Fluconazole; Atorvastatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-03
- Completion
- 2014-04
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate Cancer; EndometriosisInterventionTAK-385; Fluconazole; AtorvastatinPhasePhase 1Registry statusCompletedA Long-term Extension Study of TAK-385 in the Treatment of Endometriosis
NCT01452685 · start 2012-03
Registered record
- Registry ID
- NCT01452685
- Conditions
- Endometriosis
- Interventions
- Placebo; TAK-385; TAK-385; TAK-385; Leuprorelin acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2013-12
- Enrolment
- 397
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometriosisInterventionPlacebo; TAK-385; TAK-385; TAK-385 +1 morePhasePhase 2Registry statusCompleted